BioLife Solutions is advancing toward a Repligen Acquisition offering $11.25 in cash and 0.1442 Repligen common shares for each BioLife share. The HSR Waiting Period has expired, but investors still face a stockholder vote on October 5 and other closing conditions before the transaction can be completed.

Key Highlights

  • BioLife stockholders are scheduled to vote remotely on October 5 at 9:00 a.m. Eastern time.
  • The transaction uses two mergers, with BioLife becoming a wholly owned Repligen Subsidiary before the second merger.
  • Repligen agreed to acquire all outstanding BioLife common stock.
  • BioLife holders would receive $11.25 in cash and 0.1442 Repligen common shares per BioLife share.

BioLife Solutions, Inc. (NASDAQ: BLFS) is moving toward a Repligen acquisition that would pay holders $11.25 in cash and 0.1442 Repligen common shares for each BioLife common share. The transaction remains conditional on stockholder approval and other closing requirements.

Repligen Deal Sets Cash-and-Stock Consideration

Repligen agreed to acquire all outstanding BioLife common stock under the Merger agreement entered into on July 21, 2026. The first merger would place BioLife as a direct, wholly owned Repligen subsidiary, after which that surviving entity would merge into a Repligen subsidiary.

HSR Review Ends Before Stockholder Vote

Completion still depends on adoption of the merger agreement by BioLife stockholders and the satisfaction or Waiver of other customary closing conditions. The stated consideration combines cash with Repligen common stock, meaning the transaction is not structured as a cash-only payment to BioLife holders.